Introduction: Benzodiazepines (BZDs) are a widely prescribed class of psychoactive drugs used in the treatment of various neuropsychiatric disorders, including insomnia and anxiety. In addition to their anxiolytic and hypnotic properties, BZDs possess anticonvulsant and muscle relaxant effects, expanding their therapeutic range. Their primary mechanism of action involves the potentiation of γ-amino butyric acid (GABA), an inhibitory neurotransmitter, leading to reduced neuronal excitability and alleviation of stress and anxiety. Although BZDs are generally considered safe for short-term use, extended or frequent administration can lead to tolerance, dependence, and significant adverse drug reactions (ADRs). This comprehensive review delves into the ADRs associated with both traditional benzodiazepines and newer benzodiazepine receptor agonists such as zopiclone, zolpidem, abecarnil, and bretazenil. Drawing on extensive pharmacological, clinical, and epidemiological research, we aim to elucidate the link between BZD use and adverse outcomes, highlighting both short-term effects such as over-sedation and paradoxical reactions, and long-term risks including memory impairment, depressive symptoms, tolerance, and physical dependence. Moreover, the rising trend of recreational BZD abuse, often in the context of polydrug use, presents additional health risks, particularly for individuals with a history of substance abuse or personality disorders. This review underscores the importance of careful prescribing, vigilant monitoring, and individualized risk assessment to mitigate the adverse effects of BZDs and their analogs in clinical practice.